このサービスはあなたの地域では利用できません。

ABT

カナダ

設立年

2018 (8 年)

設立

最終オンライン: 最近の活動なし

ウェブサイトにアクセス

TrustScore は利用できませんトレンドを表示するのに十分なスコアがありません。

この会社で最初に評価・レビューしましょう。

総合スコア

ライセンス

--/40

レビュー

--/60

レビュー 0 件

TrustFinance提供

TrustScore は利用できませんトレンドを表示するのに十分なスコアがありません。

この会社で最初に評価・レビューしましょう。

規制された

推奨

IUX

(2,282 レビュー)

Mauritius

2016

(10 年)

セキュリティ情報 :

FSCA

FSC

ASIC

セキュリティ情報

警告

この会社は現在未証明.

潜在的なリスクにご注意ください！

ライセンス

A級ライセンス

世界的に有名な規制当局によって発行されたこれらのライセンスは、厳格なコンプライアンス、資金の分別管理、保険、定期的な監査を通じて、トレーダーを最大限に保護します。紛争解決とAML/CTF基準の遵守は、セキュリティをさらに強化します。

B級ライセンス

尊敬される地域規制当局によって付与されたこれらのライセンスは、資金の分別管理、財務報告、補償制度などの強固な安全対策を提供します。ティア1ほど厳格ではありませんが、信頼できる地域保護を提供します。

C級ライセンス

新興市場の規制当局によって発行されたこれらのライセンスは、最低資本要件やAMLポリシーなどの基本的な保護を提供します。監督はそれほど厳格ではないため、トレーダーは注意して安全対策を確認する必要があります。

D級ライセンス

監督が最小限の司法管轄区からのこれらのライセンスは、資金の分別管理や保険などの重要な保護を欠いていることがよくあります。運用上の柔軟性には魅力的ですが、トレーダーにとってのリスクが高くなります。

会社情報

知り合う ABT

会社情報

知り合う ABT

ABT GROUP LTD, operating under the brand name ABT, is a financial services provider that offers online trading through the MetaTrader 5 (MT5) platform. The company provides access to leveraged trading on a variety of asset classes, including foreign exchange, global indices, precious metals, energies, and cryptocurrencies. Registered in the offshore jurisdiction of St. Vincent and the Grenadines, the firm targets a global retail trading audience.

産業

外国為替小売ブローカー主要
暗号通貨暗号通貨
金融財務アドバイス

ソフトウェア

データがありません

このセクションは空のようです。すぐに更新情報をお待ちください！

お問い合わせ

ソーシャル

レビュー

ABT レビュー

レビュー

合計 0

ソート

フィルター

会社情報

知り合う ABT

会社情報

知り合う ABT

ABT GROUP LTD, operating under the brand name ABT, is a financial services provider that offers online trading through the MetaTrader 5 (MT5) platform. The company provides access to leveraged trading on a variety of asset classes, including foreign exchange, global indices, precious metals, energies, and cryptocurrencies. Registered in the offshore jurisdiction of St. Vincent and the Grenadines, the firm targets a global retail trading audience.

産業

外国為替小売ブローカー主要
暗号通貨暗号通貨
金融財務アドバイス

ソフトウェア

データがありません

このセクションは空のようです。すぐに更新情報をお待ちください！

お問い合わせ

ソーシャル

ニュース

TrustFinance 情報機関

調査日: 4月 28, 2026

The website indicates that the training data is current only up to October 2023.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

TrustFinance AI分析による提供

ニュース

TrustFinance 情報機関

調査日: 4月 28, 2026

The website indicates that the training data is current only up to October 2023.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

TrustFinance AI分析による提供

ABT

IUX

会社情報

会社情報

レビュー

ABT レビュー

レビュー

合計 0

ABT

IUX

会社情報

会社情報

ABT を見ているユーザーは他にも…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

ニュース

TrustFinance 情報機関

The website indicates that the training data is current only up to October 2023.

レビュー

ABT レビュー

レビュー

合計 0

ABT を見ているユーザーは他にも…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

ニュース

TrustFinance 情報機関

The website indicates that the training data is current only up to October 2023.